PNC Financial Services Group Inc. Sells 14,523 Shares of Solventum Corporation $SOLV

PNC Financial Services Group Inc. reduced its holdings in shares of Solventum Corporation (NYSE:SOLV) by 8.4% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 157,848 shares of the company’s stock after selling 14,523 shares during the period. PNC Financial Services Group Inc. owned about 0.09% of Solventum worth $12,508,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. LSV Asset Management lifted its stake in shares of Solventum by 364.5% during the 3rd quarter. LSV Asset Management now owns 35,122 shares of the company’s stock worth $2,564,000 after acquiring an additional 27,561 shares during the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in shares of Solventum by 15.3% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock worth $22,469,000 after acquiring an additional 40,812 shares during the last quarter. Davis Selected Advisers lifted its stake in shares of Solventum by 0.5% during the 3rd quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock worth $402,786,000 after acquiring an additional 24,950 shares during the last quarter. Appleton Partners Inc. MA bought a new stake in shares of Solventum during the 4th quarter worth approximately $7,008,000. Finally, SG Americas Securities LLC lifted its stake in shares of Solventum by 92.3% during the 4th quarter. SG Americas Securities LLC now owns 93,681 shares of the company’s stock worth $7,423,000 after acquiring an additional 44,970 shares during the last quarter.

Insider Activity

In related news, Director Amy Mcbride Wendell purchased 1,475 shares of the business’s stock in a transaction dated Tuesday, March 10th. The shares were acquired at an average cost of $68.03 per share, for a total transaction of $100,344.25. Following the acquisition, the director owned 5,039 shares of the company’s stock, valued at $342,803.17. The trade was a 41.39% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.24% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company decreased their price target on Solventum from $83.00 to $70.00 and set an “equal weight” rating for the company in a research note on Wednesday, May 6th. Rothschild & Co Redburn assumed coverage on Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price for the company. Stifel Nicolaus decreased their target price on Solventum from $105.00 to $90.00 and set a “buy” rating for the company in a research report on Wednesday, May 6th. Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research report on Sunday, March 8th. Finally, BTIG Research reaffirmed a “buy” rating and set a $89.00 target price on shares of Solventum in a research report on Wednesday, May 6th. Eight equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $84.25.

Solventum Trading Up 0.2%

Shares of NYSE SOLV opened at $76.92 on Friday. The company has a quick ratio of 0.75, a current ratio of 1.07 and a debt-to-equity ratio of 0.96. The business has a fifty day simple moving average of $68.68 and a two-hundred day simple moving average of $74.77. The firm has a market cap of $13.32 billion, a PE ratio of 9.43, a price-to-earnings-growth ratio of 1.19 and a beta of 0.59. Solventum Corporation has a twelve month low of $62.38 and a twelve month high of $88.20.

Solventum (NYSE:SOLV) last issued its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.35 by $0.13. The business had revenue of $2.01 billion during the quarter, compared to analyst estimates of $1.97 billion. Solventum had a return on equity of 23.51% and a net margin of 17.33%.Solventum’s revenue was down 3.0% on a year-over-year basis. During the same period in the previous year, the company posted $1.34 EPS. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. Analysts expect that Solventum Corporation will post 6.57 earnings per share for the current fiscal year.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.